Litigation Details for WALGREEN CO. v. ABBOTT LABORATORIES (E.D. Pa. 2015)
✉ Email this page to a colleague
WALGREEN CO. v. ABBOTT LABORATORIES (E.D. Pa. 2015)
| Docket | ⤷ Sign Up | Date Filed | 2015-03-09 |
| Court | District Court, E.D. Pennsylvania | Date Terminated | 2015-03-26 |
| Cause | 15:1 Antitrust Litigation | Assigned To | Jan Ely DuBois |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 6,080,428; 6,129,930; 6,406,715; 6,469,035; 6,676,967; 6,746,691; 6,818,229 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in WALGREEN CO. v. ABBOTT LABORATORIES
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for WALGREEN CO. v. ABBOTT LABORATORIES (E.D. Pa. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-03-09 | 1 | seven patents to cover the formulation and use of Niaspan: Patent No. 6,080,428 (the ‘428 Patent); Patent…the ‘930 Patent); Patent No. 6,406,715 (the ‘715 Patent); Patent No. 6,469,035 (the ‘035 Patent); Patent…No. 6,676,967 (the ‘967 Patent); Patent No. 6,746,691 (the ‘691 Patent); Patent No. 6,818,229 17 Case… 18 of 50 (the ‘229 Patent). In addition, Kos purchased two more patents: Patent Nos. 5,126,145 and 5,268,181… this time, the patent litigation continued Launching before the conclusion of patent litigation under | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
